or Try an Advanced Search...

    Non Small Cell Lung Cancer Stocks List

    Symbol Grade Name % Change
    TIL C Instil Bio, Inc. -2.54
    HCM C Hutchison China MediTech Limited -3.77
    GMAB D Genmab A/S 1.11
    GNLX F Genelux Corporation 1.39
    EVAX D Evaxion Biotech A/S -2.87
    CRIS D Curis, Inc. -6.35
    CGEM C Cullinan Management, Inc. -2.69
    CNTA D Centessa Pharmaceuticals plc -0.89
    CCCC F C4 Therapeutics, Inc. -4.86
    BCAB D BioAtla, Inc. -8.71
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Instruments & Supplies
    Related Stock Lists: Cancer Clinical Medicine Biopharmaceutical Medicine Cancer Immunotherapy Drugs Melanoma Solid Tumors Immunotherapies Immunotherapy Multiple Myeloma Small Cell Lung Cancer Acute Myeloid Leukemia Antibodies Biotechnology Bladder Cancer Cell Therapy Cervical Cancer Cutaneous Squamous Cell Carcinoma Drug Discovery

    Related ETFs - A few ETFs which own one or more of the above listed Non Small Cell Lung Cancer stocks.

    Symbol Grade Name Weight
    CNCR D Loncar Cancer Immunotherapy ETF 5.8
    FBT C First Trust Amex Biotech Index Fund 3.25
    BBC D Virtus LifeSci Biotech Clinical Trials ETF 2.52
    IBB B iShares Nasdaq Biotechnology Index Fund 1.75
    FDM A First Trust DJ Select MicroCap ETF 1.55
    View all Non Small Cell Lung Cancer ETFs...
    Compare ETFs
    Compare BBC to FDM Compare CNCR to IBB Compare FBT to IBB

        Non Small Cell Lung Cancer Stocks Recent News

        Date Stock Title
        May 17 HCM HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
        May 16 CGEM Cullinan Therapeutics files to sell 14.4M shares of common stock for holders
        May 16 CGEM Cullinan Therapeutics reports Q1 results
        May 15 CGEM Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
        May 15 GMAB Market Chatter: Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'
        May 15 BCAB BioAtla Inc (BCAB) (Q1 2024) Earnings Call Transcript Highlights: Strategic Adjustments and ...
        May 15 BCAB BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript
        May 14 BCAB BioAtla GAAP EPS of -$0.48 beats by $0.06
        May 14 BCAB BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
        May 14 CRIS Curis Announces Additional Data from TakeAim Leukemia Study
        May 14 GMAB Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
        May 14 GMAB Danish biotech says companies should tap into China’s ‘impressive innovation’
        May 14 HCM HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
        May 14 HCM HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
        May 13 CNTA Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
        Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Instruments & Supplies
        Related Stock Lists: Cancer Clinical Medicine Biopharmaceutical Medicine Cancer Immunotherapy Drugs Melanoma Solid Tumors Immunotherapies Immunotherapy Multiple Myeloma Small Cell Lung Cancer Acute Myeloid Leukemia Antibodies Biotechnology Bladder Cancer Cell Therapy Cervical Cancer Cutaneous Squamous Cell Carcinoma Drug Discovery
        Non Small Cell Lung Cancer

        Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases. It is a type of cancer that begins in the cells that line the airways of the lungs. NSCLC is divided into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Symptoms of NSCLC include a persistent cough, chest pain, shortness of breath, and coughing up blood. Treatment options for NSCLC include surgery, chemotherapy, radiation therapy, and targeted therapy.

        Browse All Tags